¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"GABA Plasma Membrane Transport Proteins"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® hyaline membrane disease ÇÑ±Û À¯¸®Áú¸·º´
¼³¸í   
  ÇãÆÄ ¼º¼÷µµÀÇ ¹Ì¼÷À¸·Î ÇãÆÄ²Ê¸®¸¦ ÆØÃ¢½Ã۴ ¹°Áú(Ç¥¸éȰ¼ºÁ¦)ÀÌ ºÎÁ·ÇÏ¿© È£Èí°ï¶õÀÌ ÃÊ·¡µÇ´Â º´À¸·Î¼­ ¹Ì¼÷¾Æ¿¡ È£¹ßÇϴµ¥, Ãâ»ý½Ã ÀӽűⰣº¸´Ùµµ ÇãÆÄ ¼º¼÷ Á¤µµ°¡ ´õ °ü¿©µÈ´Ù. ´ÜÀÏ º´À¸·Î¼­´Â »ç¸Á·üÀÌ °¡Àå ³ôÀ¸¸ç(¾à 30%), ½Å»ý¾ÆÀÇ ´ëÇ¥ÀûÀΠº´ÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ¹Ì¼÷¾Æ, »ýÈÄ 6~8½Ã°£³» È£Èí°ï¶õÁõ¼¼ ÃâÇö°ú »ýÈÄ 24~48½Ã°£ÀÇ Áõ»ó ¾ÇÈ­, »ýÈÄ 2~3Àϰ£ ÀΰøÀûÀ¸·Î »ê¼Ò¸¦ °ø±ÞÇÏÁö ¾ÊÀ¸¸é È£ÈíÀ» °è¼Ó½Ãų ¼ö°¡ ¾øÀ¸¸ç Á¡Á¡´õ »ê¼ÒÀÇ °ø±Þ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö¸ç, µ¿¸ÆÇ÷¾×¼ÓÀÇ »ê¼Ò³óµµ°¡ ³»·Á°¡°í ÀÌ»êȭź¼ÒÀÇ ³óµµ°¡ ³ôÀ¸¸ç, ÈäºÎ ¹æ»ç¼± ¼Ò°ßÀ» ÂüÀÛÇÏ¿© Áø´ÜÇÑ´Ù. È¯¾Æ´Â ¼÷·ÃµÈ °£È£ Àη°ú Ã·´Ü ÀÇ·á Àåºñ°¡ ¼³Ä¡µÈ ½Å»ý¾Æ ÁýÁß Ä¡·á½Ç¿¡¼­ Ä¡·áÇÏ¿©¾ß ÇÑ´Ù. ¿¹ÈĴ Áõ¼¼ÀÇ °æÁß¿¡ µû¶ó ´Ù¸£°í »ç¸Á·üÀº 30~50% µÈ´Ù. ¾î¶² ¾Æ±â¿¡ À־´Â Ä¡·á ÈÄ¿¡ ´«À̳ª ±â°üÁöÇãÆÄ °èÅë¿¡ Àå¾Ö¸¦ ÀÏÀ¸Å°´Â »ê¼ÒÁßµ¶ÁõÀÌ º¸°íµÇ°í ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • human plasma protein fraction
    »ç¶÷Ç÷Àå´Ü¹éºÐÀ²
  • interstitial plasma cell pneumonia
    »çÀÌÁúÇüÁú¼¼Æ÷Æó·Å, ÆóÆ÷ÀÚÃæÁõ
  • normal human plasma
    Á¤»ó»ç¶÷Ç÷Àå
  • plasma
    1. Ç÷Àå 2. ¿øÇüÁú, ¼¼Æ÷Áú
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷Áúȯ
  • plasma cell granuloma
    ÇüÁú¼¼Æ÷À°¾ÆÁ¾
  • plasma cell mastitis
    ÇüÁú¼¼Æ÷À¯¹æ¿°
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾
  • plasma coagulase
    Ç÷ÀåÀÀ°íÈ¿¼Ò
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma cross matching
    Ç÷Àå±³Â÷½ÃÇè
  • plasma exchange
    Ç÷À屳ȯ(¼ú)
  • plasma expander
    Ç÷ÀåÁõ·®Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • thin basement membrane disease
    ¾ãÀº¹Ù´Ú¸·º´, ¾ãÀº±âÀú¸·º´
  • membrane
    ¸·
  • amnionic membrane
    ¾ç¸·
  • arachnoid membrane
    °Å¹Ì¸·
  • basement membrane
    ¹Ù´Ú¸·, ±âÀú¸·
  • mucous membrane
    Á¡¸·
  • nuclear membrane
    ÇÙ¸·
  • periorbital membrane
    (¢¡ periorbita) ´«È®»À¸·, ¾È¿Í°ñ¸·
  • semipermeable membrane
    ¹ÝÅõ¸·
  • serous membrane
    À帷
  • slit membrane
    Æ´»õ¸·
  • spiral membrane
    ³ª¼±¸·, °í½Ç°è´Üº®
  • synovial membrane
    À±È°¸·
  • tarsal membrane
    (¢¡orbital septum) ´«È®»çÀ̸·, ¾È¿Í°Ý¸·
  • urogenital membrane
    ºñ´¢»ý½Ä¸·
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • transport number
    À̵¿ºÐÀ²
  • passive transport
    ¼öµ¿¿î¹Ý
  • supersonic transport
    ÃÊÀ½ÆÄ¼ö¼Û
  • transport
    ¿î¹Ý
  • transcapillary transport
    ¸ð¼¼°ü¿î¹Ý
  • transmembrane transport
    ¸·¿î¹Ý
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå
  • blood plasma
    Ç÷Àå
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma coagulase
    Ç÷ÀåÀÀ°íÈ¿¼Ò
  • thromboplastin plasma component
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾Ç÷À强ºÐ
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷Áúȯ
  • effective renal plasma flow
    À¯È¿ÄáÆÏÇ÷Àå·ù·®
  • plasma exchange
    Ç÷À屳ȯ, Ç÷À屳ȯ¼ú
  • plasma volume expander
    ÀΰøÇ÷ÀåÁõ·®Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد), ¼¼Æ÷ÇüÁú¸·(á¬øàû¡òõد).
  • plasma membrane
    ÇüÁú¸·
  • plasma membrane
    ¿øÇüÁú¸·
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد), ¼¼Æ÷ÇüÁú¸·(á¬øàû¡òõد).
  • plasma membrane of erythrocyte
    ÀûÇ÷±¸ÇüÁú¸·
  • ERPF => effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
  • ERPF=£¾effective renal plasma flow
    À¯È¿½ÅÇ÷·ù·®.
  • RPF => renal plasma flow
    ½ÅÇ÷Àå·ù(·®)
  • RPR test => rapid plasma reagin test
    ½Å¼ÓÇ÷À帮¾ÆÁø<°¨ÀÛÇ×ü>½ÃÇè
  • TPC=£¾thromboplastin plasma component
    Æ®·Òº¸ÇÃ¶ó½ºÆ¾Ç÷À强ºÐ.
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (¡­úìíì).
  • antihemophilic plasma
    Ç×Ç÷¿ìº´Ç÷Àå (?Ì´Ëö).
  • fresh frozen plasma=FFP
    ½Å¼±µ¿°áÇ÷Àå
  • plasma
    Ç÷Àå(úìíì), ÇöóÁ.
  • plasma
    Ç÷Àå
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma membrane
    ÇüÁú¸·
  • plasma membrane of erythrocyte
    ÀûÇ÷±¸ÇüÁú¸·
  • trilaminar plasma membrane
    »ïÃþ ¿øÇüÁú¸·
  • oropharyngeal membrane [buccopharyngeal membrane]
    ÀÔÀεθ·
  • vestibular wall [vestibular membrane, reissners membrane]
    ¾È¶ã°è´Üº® [¾È¶ã¸·]
  • active transport
    ´Éµ¿(Àû)¿î¹Ý(¡­îÜê¡Úæ), ´Éµ¿(Àû)¼ö¼Û(ÒöÔÑîÜâÃáê)
  • carbon dioxide transport
    ÀÌ»êȭź¼Ò ¿î¹Ý(ê¡Úæ)(À̵¿,¼ö¼Û)
  • carrier mediated transport
    ¿î¹Ýü¸Å°³ À̵¿
  • catalysed transport
    Ã˸żö¼Û.
  • co-transport = symport
    °øµ¿¿î¹Ý(À̵¿, ¼ö¼Û)(ÍìÔÒê¡Úæ)
  • component, T (transport)
    T¼ººÐ, ¼ö¼Û¼ººÐ
  • counter transport
    ¿ª¹æÇâ(æ½Û°ú¾)°øµ¿¿î¹Ý(À̵¿, ¼ö¼Û)
  • diffusion-limited transport
    È®»êÁ¦ÇѼö¼Û
  • downhill transport =passive t.
    Çǵ¿¿î¹Ý(ù¬ÔÑê¡Úæ).
  • facilitated transport
    ÃËÁø¼ö¼Û(¡­âÃáê).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Tympanic membrane
    °í¸· [±Íû]
    [¿¾ ¿ë¾î] °í¸·º®
  • Branches to tympanic membrane
    °í¸·°¡Áö
    [¿¾ ¿ë¾î] °í¸·Áö
  • Umbo of tympanic membrane
    °í¸·¹è²Å
    [¿¾ ¿ë¾î] °í¸·Á¦
  • Recesses of tympanic membrane
    °í¸·¿À¸ñ
    [¿¾ ¿ë¾î] °í¸·ÇÔ¿ä
  • Tympanic wall [Spiral membrane]
    °í½Ç°è´Üº® [³ª¼±¸·]
    [¿¾ ¿ë¾î] °í½Çº®
  • Tympanic wall of cochlear duct [Spiral membrane]
    °í½Ç°è´Üº® [³ª¼±¸·]
    [¿¾ ¿ë¾î] °í½Ç°èº®
  • Mucous membrane of tympanic cavity
    °í½ÇÁ¡¸·
    [¿¾ ¿ë¾î] °í½ÇÁ¡¸·
  • Reticular membrane
    ±×¹°¸·
    [¿¾ ¿ë¾î] ¼¼¸Á¸·
  • Vitelline membrane
    ³­È²¸·
    [¿¾ ¿ë¾î] ³­È²¸·
  • Endothelioendothelial membrane
    ³»ÇÇ»çÀ̸·
    [¿¾ ¿ë¾î] ³»Çǰ£¼ºÇ÷°£°³À縷
  • Endotheliochorial membrane
    ³»ÇÇÀ¶¸ð¸·
    [¿¾ ¿ë¾î] ³»ÇÇÀ¶¸ð¸·¼ºÇ÷°£°³À縷
  • Quadrangular membrane
    ³×¸ð¸·
    [¿¾ ¿ë¾î] »ç°¢¸·
  • Periventricular glial limiting membrane
    ³ú½ÇÁÖÀ§¾Æ±³°æ°è¸·
    [¿¾ ¿ë¾î] ³ú½ÇÁÖÀ§°æ°è¸·
  • Tectorial membrane
    µ¤°³¸·
    [¿¾ ¿ë¾î] °³¸·
  • Tectorial membrane
    µ¤°³¸·
    [¿¾ ¿ë¾î] Çǰ³¸·
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • split proteins
    ºÐ¸® ´Ü¹éÁú(ÝÂ×îÓ±ÛÜòõ)
  • stress proteins
    ½ºÆ®·¹½º ´Ü¹éÁú(Ó±ÛÜòõ)
  • tau proteins
    Ÿ¿ì ´Ü¹éÁú (Ó±ÛÜòõ)
  • whey proteins
    À¯Àå(êáíì) ´Ü¹éÁú(Ó±ÛÜòõ)
  • blood plasma
    Ç÷Àå(úìíì)
  • native plasma
    ÀÚ¿¬(í»æÔ) Çö󽺸¶
  • plasma
    "Ç÷Àå(úìíì), ÇöóÁ"
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà)
  • plasma clearance
    Ç÷ÀåûÁ¤(úìíìôèïä)
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­)
  • plasma gel
    Á©»ó(ßÓ) ¿øÇüÁú(ê«û¡òõ)
  • plasma lipoproteins
    Ç÷Àå(úìíì) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • plasma sol
    Á¹»ó(ßÓ) ¿øÇüÁú(ê«û¡òõ)
  • plasma-specific enzyme
    Ç÷À寝ÀÌ È¿¼Ò(úìíì÷åì¶ý£áÈ)
  • plasma thromboplastic factor
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ(úìíìúìîûû¡à÷ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PBPs Penicillin-Binding Proteins
GABAT, GABA-T gamma-aminobutyric acid transaminase
PVM pneumonia virus of mice; proteins, vitamins, and minerals
RPSP reference preparation for serum proteins
FENa, FeNa Fractional Excretion of Sodium
  ; VolumeÀÇ °³³äÀ» Á¦°ÅÇÏ¿© Á» ´õ Á¤È®ÇÑ ½ÅÀåÀÇ ³óÃà ´É·ÂÀ» Æò°¡,
 &n...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
G proteins GIP-binding proteins
G-proteins GTP)-binding regulatory proteins
G-proteins Guanine nucleotide-binding regulatory proteins
G proteins reglatory proteins
MP Membrane proteins
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • malignant plasma cell
    ¾Ç¼º ÇüÁú ¼¼Æ÷
  • pathologic plasma protein
    º´Àû Ç÷Àå ´Ü¹é
  • plasma cell
    ÇüÁú±¸, Ç÷Àå ¼¼Æ÷, ÇüÁú ¼¼Æ÷
    1. Ç×ü¸¦ ºÐºñÇÒ ¼ö ÀÖ´Â ¼¼Æ÷. 2. ¸¸¼º ¿°ÁõÀ̳ª ƯÁ¤ Áúȯ »óÅÂ, ¶Ç´Â Á¾¾ç¿¡¼­ ³ªÅ¸³ª´Â ¼¼Æ÷·Î ¼øÈ¯ Ç÷¾×¿¡ Á¤»óÀûÀ¸·Î ³ªÅ¸³ªÁö´Â ¾Ê´Â´Ù. Å©±â´Â Àӯı¸º¸´Ù Å©¸ç, È£¿°±â¼ºÀÇ ¿°»öÁúÀ» °¡Áö´Â ÇÙÀÌ ¼¼Æ÷ÀÇ Á߽ɿ¡¼­ ¹þ¾î³ª ½Ã°èÀÇ ¼ýÀÚÆÇÀÇ ¼ýÀÚµéó·³ º¯¿¬¿¡ À§Ä¡Çϰí ÀÖ´Ù. ÀÌ ¼¼Æ÷ÀÇ ±â¿ø¿¡ °üÇØ¼­´Â
  • plasma cell dyscrasia
    Ç÷Àå ¼¼Æ÷ ÀÌ»ó
  • plasma cell pneumonia
    ÇüÁú ¼¼Æ÷¼º Æó·Å
  • plasma cloud
    Çö󽺸¶ ±¸¸§
  • plasma cortisol
    Ç÷Àå ÄÚÆ¼Á¹
  • plasma extravasation
    Ç÷Àå À¯Ãâ, Ç÷Àå ÀÏÇ÷
  • plasma formation
    Çö󽺸¶ Çü¼º
  • plasma hemoglobin
    Ç÷Àå Çì¸ð±Û·Îºó, Ç÷Àå Ç÷¾×¼Ò
  • plasma protein
    Ç÷Àå ´Ü¹é, Ç÷Àå ´Ü¹éÁú
    1. Ç÷Àå¿¡ Á¸ÀçÇÏ´Â ¿©·¯ Á¾·ùÀÇ ´Ü¹éÁú. ¿î¹Ý ´Ü¹éÁú
  • plasma protein binding
    Ç÷Àå ´Ü¹é °áÇÕ
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
  • plasma substitute
    Ç÷Àå ´ë¿ëÁ¦
  • plasma thromboplastin antecedent deficiency
    PTA °áÇÌÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
GABA pathway The pathway that ultimately converts 4-aminobutyrate to succinate; succinate is then converted to alpha-ketoglutarate, via the tricarboxylic acid cycle, which is then acted upon by glutamate dehydrogenase; glutamate is then decarboxylated to reform 4-aminobutyrate; an important pathway for those cells which make this neuroactive molecule.
Synonym: GABA pathway.
(05 Mar 2000)
GABA permease <chemical> From aspergillus nidulans; uga4 is from saccharomyces cerevisiae
Synonym: gamma-amino-n-butyrate permease, 4-aminobutyric acid permease, uga4 protein, uga4 gene product
(26 Jun 1999)
GABA receptor <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B.
A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor.
See: amino acid receptor superfamily.
B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines.
(05 Jan 1998)
receptors, gaba Cell-surface proteins that bind gaba with high affinity and trigger changes that influence the behaviour of cells. Gaba-a receptors control chloride channels formed by the receptor complex itself. They are blocked by bicuculline and usually have modulatory sites sensitive to benzodiazepines and barbiturates. Gaba-b receptors act through g-proteins on several effector systems, are insensitive to bicuculline, and have a high affinity for l-baclofen.
(12 Dec 1998)
receptors, gaba-a Cell surface proteins which bind gaba and control an integral membrane chloride channel. Gaba-a receptors are the most prevalent inhibitory neurotransmitter receptors in the brain. Several isoforms have been cloned, and they belong to a superfamily which includes nicotinic receptors, glycine receptors, and 5ht-3 receptors. Most gaba-a receptors have separate modulatory sites sensitive to benzodiazepines and to barbiturates.
(12 Dec 1998)
receptors, gaba-b Cell surface proteins which bind gaba and influence cells via interactions with g-proteins. Gaba-b receptors are pharmacologically characterised by their insensitivity to the blocker bicuculline and sensitivity to the agonist l-baclofen. They are found both presynaptically and postsynaptically, and act variously by inhibition of adenylate cyclase, activation of phospholipase a2, activation of potassium channels, and inactivation of voltage-activated calcium channels.
(12 Dec 1998)
active transport <biochemistry, chemistry> Transport of ions, nutrients or other molecules into a cell against a concentration gradient, this requires the expenditure of energy through ATP hydrolysis.
(06 May 1997)
anterograde transport Movement of material from the cell body of a neuron into axons and dendrites retrograde axoplasmic transport also occurs).
(18 Nov 1997)
atrial transport function The role of the atria in filling and stretching the ventricles by their presystolic contraction, without which the force of ventricular contraction and hence the cardiac output may significantly decrease.
(05 Mar 2000)
axonal transport Directed transport of organelles and molecules along a nerve cell axon. Transport can be anterograde (from the cell body) or retrograde (toward the cell body). (alberts et al., molecular biology of the cell, 3d ed, pg3)
(12 Dec 1998)
axoplasmic transport Transport by way of flow of axoplasm toward cell soma (retrograde) or toward axon terminal (anterograde).
(05 Mar 2000)
biological transport The movement of materials (including biochemical substances and drugs) across cell membranes and epithelial layers, usually by passive diffusion.
(12 Dec 1998)
biological transport, active The movement of materials across cell membranes and epithelial layers against an electrochemical gradient, requiring the expenditure of metabolic energy.
(12 Dec 1998)
vectorial transport <physiology> Transport of an ion or molecule across an epithelium in a certain direction (e.g. absorption of glucose by the gut). Vectorial transport implies a nonuniform distribution of transport proteins on the plasma membranes of two faces of the epithelium.
(06 Mar 2000)
paracellular transport Solvent movement across an epithelial cell layer through the tight junctions between cells.
Compare: transcellular transport.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • transport
    ¼ö¼Û(±â,¼±,±â°ü);ȲȦ;µµÃë;¿­Áß;À¯Çü¼ö )
  • transport
    ¼ö¼ÛÇÏ´Ù;µµÃë(¿­Áß)ÄÉ ÇÏ´Ù;À¯Çü¿¡ óÇÏ´Ù;Á×ÀÌ´Ù
  • transport House
    ³ëµ¿´ç º»ºÎ
  • transport ship
    ¿î¼Û¼±
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á